Keyphrases
Intervention Studies
100%
Peripheral Arterial Disease
100%
Arterial Disease
100%
Multiple Interventions
100%
Low-density Lipoprotein
50%
High-density Lipoprotein Cholesterol (HDL-C)
50%
Warfarin
16%
Niacin
16%
Lipids
16%
Intermittent Claudication
16%
Vitamin C
16%
Quality of Life
16%
Antioxidant
16%
Vitamin E
16%
Randomized pilot Trial
16%
Ankle-brachial Index
16%
Biochemical Markers
16%
Nicotinic Acid
16%
International Normalized Ratio
16%
Antithrombotic Therapy
16%
Multiple Drugs
16%
Intervention Group
16%
Functional Status
16%
Pill Count
16%
Antioxidant Therapy
16%
Design Features
16%
Novel Design
16%
2-factorial Design
16%
Drug Regimen
16%
Lipoprotein Levels
16%
Secondary Prevention Trials
16%
β-carotene
16%
Adherence to Therapy
16%
Hydroxymethylglutaryl-CoA Reductase Inhibitors
16%
Intervention Impact
16%
Non-invasive Method
16%
Modifying Strategy
16%
Nursing and Health Professions
Pilot Study
100%
Peripheral Occlusive Artery Disease
100%
Artery Disease
100%
Low Density Lipoprotein
50%
High Density Lipoprotein
50%
Nicotinic Acid
33%
Anticoagulant Agent
33%
Antioxidant
33%
International Normalized Ratio
16%
Secondary Prevention
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%
Factorial Design
16%
Pill
16%
Combination Drug
16%
Masking
16%
Non Invasive Procedure
16%
Functional Status
16%
Ankle Brachial Index
16%
Patient Compliance
16%
Alpha Tocopherol
16%
Biochemical Marker
16%
Beta Carotene
16%
Warfarin
16%
Intermittent Claudication
16%
Efficacy
16%
Quality of Life
16%
Adherence
16%
Medicine and Dentistry
Arteriosclerosis Obliterans
100%
Artery Disease
100%
Intervention Trial
100%
Arm
50%
Low-Density Lipoprotein
50%
High-Density Lipoprotein
50%
Antioxidant
33%
Niacin
33%
Secondary Prevention
16%
Quality of Life
16%
Statin
16%
Warfarin
16%
Intermittent Claudication
16%
Masking
16%
Antithrombotic
16%
Non Invasive Procedure
16%
Antithrombotic Therapy
16%
Ankle Brachial Index
16%
Patient Compliance
16%
Functional Status
16%
Alpha Tocopherol
16%
Biochemical Marker
16%
Beta Carotene
16%
Combination Drug
16%
Pharmacology, Toxicology and Pharmaceutical Science
Intervention Trial
100%
Peripheral Occlusive Artery Disease
100%
Artery Disease
100%
Low Density Lipoprotein
50%
High Density Lipoprotein
50%
Nicotinic Acid
33%
Antioxidant
33%
Antithrombotic Therapy
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%
Anticoagulant Agent
16%
Alpha Tocopherol
16%
Functional Status
16%
Biochemical Marker
16%
Beta Carotene
16%
Combination Drug
16%
Warfarin
16%
Intermittent Claudication
16%